IDRX-42 Clinical Trials
2 recruitingDrug
Phase 11Phase 31
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Gastrointestinal Neoplasms
GlaxoSmithKline450 enrolled84 locationsNCT07218926
Recruiting
Phase 1
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
Metastatic CancerGastrointestinal NeoplasmsGastrointestinal Diseases+2 more
IDRX, Inc., a wholly owned subsidiary of GSK, LLC278 enrolled30 locationsNCT05489237